AG 013

Drug Profile

AG 013

Alternative Names: AG013; Lactococcus lactis expressing human trefoil factor 1; Lactococcus lactis secreting human trefoil factor 1

Latest Information Update: 22 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ActoGeniX
  • Developer Intrexon Corporation; Oragenics Inc
  • Class Bacteria; Peptides
  • Mechanism of Action Mucoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stomatitis

Most Recent Events

  • 17 Oct 2018 The Federal Agency for Medicines and Health Products, Belgium approves initiation of a phase II trial in Stomatitis in Belgium
  • 30 May 2018 Interim adverse events data from a phase II trial in Stomatitis released by Oragenics
  • 23 Mar 2018 Adverse events data from a phase Ib trial in Stomatitis released by Oragenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top